Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

This study could potentially impact the stock performance of Regeneron Pharmaceuticals and Sanofi, as positive results may enhance investor sentiment and market valuation. The study’s focus on COPD, a ...

Apogee Therapeutics has shared positive 16-week results from a mid-stage study of its investigational anti-IL-13 antibody in ...

Sanofi (SNY) and Regeneron's Dupixent (dupilumab) won approval for the additional indication of COPD in September 2024, making it the only biologic currently approved in the U.S. for the condition.

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Regeneron reports strong Q2 2025 growth with Dupixent sales up 21% and EYLEA HD hitting record highs. Explore key earnings insights and pipeline updates.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using patents to thwart competition.

A federal judge is contemplating whether a new trial is needed in the Tyré Nichols federal case, among a litany of other motions.